Patents Assigned to Viron Therapeutics, Inc.
  • Publication number: 20120270793
    Abstract: Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 25, 2012
    Applicant: Viron Therapeutics Inc.
    Inventor: Alexandra R. Lucas
  • Patent number: 8268331
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 18, 2012
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 8227569
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: July 24, 2012
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Publication number: 20110064757
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Application
    Filed: May 7, 2009
    Publication date: March 17, 2011
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7906483
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: March 15, 2011
    Assignee: Viron Therapeutics Inc.
    Inventors: Alexandra Lucas, Z. Robert Zhong, D. Grant McFadden
  • Publication number: 20100331524
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 30, 2010
    Applicant: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7745396
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: June 29, 2010
    Assignee: Viron Therapeutics Inc.
    Inventor: Alexandra Lucas
  • Patent number: 7718368
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: May 18, 2010
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7585507
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: September 8, 2009
    Assignee: Viron Therapeutics Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7514405
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: April 7, 2009
    Assignee: Viron Therapeutics Inc.
    Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
  • Publication number: 20090011979
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.
    Type: Application
    Filed: August 17, 2006
    Publication date: January 8, 2009
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Patent number: 7419670
    Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: September 2, 2008
    Assignee: Viron Therapeutics, Inc.
    Inventors: Robert Z. Zhong, Alexandra Lucas, Grant D. McFadden
  • Publication number: 20080070841
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Application
    Filed: September 7, 2007
    Publication date: March 20, 2008
    Applicant: Viron Therapeutics, Inc.
    Inventor: Alxandria Lucas
  • Patent number: 7285530
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Grant
    Filed: October 21, 2005
    Date of Patent: October 23, 2007
    Assignee: Viron Therapeutics, Inc.
    Inventor: Alexandra Lucas
  • Publication number: 20060286125
    Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.
    Type: Application
    Filed: May 9, 2005
    Publication date: December 21, 2006
    Applicant: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Karim Essani
  • Patent number: 7101559
    Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immune-related diseases.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: September 5, 2006
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas, Xing Li
  • Publication number: 20030171263
    Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
    Type: Application
    Filed: March 13, 2003
    Publication date: September 11, 2003
    Applicant: Viron Therapeutics, Inc.
    Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
  • Patent number: 6589933
    Abstract: The present invention provides a method of use for a novel chemokine binding protein 5(type-2 CBP) encoded by poxviruses and having amino acid sequence homology with the Shope fibroma virus T1 family of proteins against disease syndromes associated with acute or chronic dysregulated inflammatory responses.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: July 8, 2003
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas
  • Patent number: 6495515
    Abstract: The present invention provides a method of use for a novel type I chemokine binding protein encoded by poxviruses and having amino acid sequence homology with the myxoma virus T7 interferon-&ggr; receptor homolog against disease syndromes associated with acute or chronic dysregulated inflammatory responses.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: December 17, 2002
    Assignee: Viron Therapeutics, Inc.
    Inventors: Grant McFadden, Alexandra Lucas
  • Patent number: 5939525
    Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1, SERP-1 analog or biologically active fragment thereof admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. Biologically active SERP-1 analogs are also provided. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: August 17, 1999
    Assignee: Viron Therapeutics, Inc.
    Inventors: D. Grant McFadden, Alexandra Lucas